Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient

This publication has 14 references indexed in Scilit:

• Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Commentary: Varied preferences reflect the reality of clinical practice
  BMJ, 2001
• Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
  Heart, 2001
• Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis
  BMJ, 2000
• Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal Bleeding
  New England Journal of Medicine, 2000
• Using the Framingham model to predict heart disease in the United Kingdom: retrospective study
  BMJ, 2000
• Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin
  Journal of Neurology, Neurosurgery & Psychiatry, 1999
• A simple computer program for guiding management of cardiovascular risk factors and prescribing
  BMJ, 1999
• Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men
  Heart, 1999
• Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.
  Journal of Neurology, Neurosurgery & Psychiatry, 1996
• An evidence based approach to individualising treatment
  BMJ, 1995